Home » Stocks » Vaxart

Vaxart, Inc. (VXRT)

Stock Price: $9.19 USD 0.09 (0.99%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $9.30 +0.11 (1.20%) Aug 7, 7:59 PM

Stock Price Chart

Key Info

Market Cap 681.75M
Revenue (ttm) 7.80M
Net Income (ttm) -21.94M
Shares Out 109.09M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $9.19
Previous Close $9.10
Change ($) 0.09
Change (%) 0.99%
Day's Open 9.95
Day's Range 9.19 - 10.20
Day's Volume 13,781,857
52-Week Range 0.25 - 17.49

More Stats

Market Cap 681.75M
Enterprise Value 639.29M
Earnings Date (est) Nov 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 109.09M
Float 108.40M
EPS (basic) -0.36
EPS (diluted) -0.53
FCF / Share -0.16
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.77M
Short Ratio 0.12
Short % of Float 7.38%
Beta 0.34
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 87.46
PB Ratio 33.69
Revenue 7.80M
Operating Income -19.56M
Net Income -21.94M
Free Cash Flow -12.00M
Net Cash 42.46M
Net Cash / Share 0.57
Gross Margin -60.01%
Operating Margin -250.93%
Profit Margin -281.50%
FCF Margin -153.92%
ROA -17.91%
ROE -78.26%
ROIC 1,996.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$14.50*
(57.78% upside)
Low
7.00
Current: $9.19
High
22.00
Target: 14.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue9.864.165.849.3024.6068.7033.6020.4012.5035.01
Revenue Growth137.12%-28.77%-37.22%-62.2%-64.19%104.46%64.71%63.2%-64.29%-
Gross Profit9.864.165.849.3021.0017.6013.9010.5010.0031.05
Operating Income-15.79-21.76-10.02-25.00-26.00-10.10-24.00-23.00-30.50-1.20
Net Income-18.65-18.01-9.58-25.40-19.10-11.00-8.90-19.20-25.400.88
Shares Outstanding21.576.320.143.513.212.852.572.062.050.67
Earnings Per Share-0.86-2.90-91.65-7.26-5.94-3.85-3.52-9.35-12.321.32
Operating Cash Flow-13.09-14.55-10.04-14.10-9.60-3.30-13.90-15.90-33.7039.93
Capital Expenditures-0.85-0.71-0.05-0.200.30-0.10-1.00-1.30-0.70-0.10
Free Cash Flow-13.94-15.26-10.09-14.30-9.30-3.40-14.90-17.20-34.4039.83
Cash & Equivalents13.5311.512.9969.0057.6081.7066.8053.80102108
Total Debt2.313.6140.250.701.00-----
Net Cash / Debt11.217.90-37.2668.3056.6081.7066.8053.80102108
Assets37.0335.234.5272.7079.4011485.8069.30105114
Liabilities24.0823.9943.2526.509.9027.1017.8010.0045.6453.30
Book Value12.9511.24-38.7246.2069.5086.9068.0059.3059.7060.57
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vaxart, Inc.
Country United States
Employees 14
CEO Andrei Floroiu

Stock Information

Ticker Symbol VXRT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VXRT

Description

Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.